Erectile dysfunction is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It is a multifactorial condition with organic, psychogenic, and mixed etiologies, and is strongly associated with cardiometabolic comorbidities and age. It can substantially affect quality of life and mental health.
New studies link GLP-1 drugs to eating disorders, erectile dysfunction and relationship changes, while Deloitte reports the drugs' market boom has lifted pharma R&D returns but created a concentration risk.
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
GLP-1 drugs are expanding in 2026 with oral semaglutide for weight management, rising patient use and broader commercialization. A study also found a modest increase in erectile dysfunction risk among men with Type 2 diabetes starting GLP-1 medicines, though the association weakened after stricter adjustment.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Ten-year survival data show salvage focal therapy using heat or cold ablation is as effective as radical prostatectomy for treating localized prostate cancer recurrence after radiotherapy, with significantly fewer complications and better quality of life.
A major meta-analysis of 19 randomized trials involving 123,940 participants found that only six side effects are actually caused by statins, challenging long-standing concerns about the drugs' safety profile.
Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.
A matched analysis of 923 men found salvage focal therapy and radical prostatectomy achieved comparable 10-year cancer-specific survival for prostate cancer recurring after radiotherapy, though surgery carried significantly higher complication rates.
The Trump administration launched TrumpRx.gov in February 2026, offering discounted prices on dozens of brand-name prescription drugs through negotiated deals with pharmaceutical companies, though critics warn many listed drugs have cheaper generic alternatives.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07762469 |
Diagnostic Performance of a Flexible Penile Monitoring System for ED |
NOT_YET_RECRUITING | |
| NCT07761806 |
Comparsion of Effect of PRP,PDE5 Inhibitor in Treatment of Erectile Dysfunction |
COMPLETED | PHASE2/PHASE3 |
| NCT07758842 |
Lifestyle Modification for Erectile Dysfunction in Men With Metabolic Syndrome |
RECRUITING | NA |
| NCT07753720 |
Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction |
RECRUITING | PHASE4 |
| NCT07719790 |
Does Erectile Dysfonction Allow to Evaluate Subendocardial Viability Among Treated Patients With Hypertension ? |
NOT_YET_RECRUITING | |
| NCT07715448 |
Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia |
COMPLETED | PHASE4 |
| NCT07692867 |
Efficacy and Safety Study of Tunodafil Hydrochloride Tablets in Erectile Dysfunction |
COMPLETED | PHASE3 |
| NCT07685249 |
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment |
NOT_YET_RECRUITING | NA |
| NCT07676617 |
Satisfaction of Patients With Erectile Dysfunction With the Use of Sildenafil Oral Suspension Compared to Orodispersible Tablets |
ACTIVE_NOT_RECRUITING | |
| NCT07668973 |
Comparison Between Excision And Primary Anastomosis Urethroplasty And Tunica Vaginalis Graft Urethroplasty. |
NOT_YET_RECRUITING | NA |
